Head-to-head · WeighScore
AM Rx vs RxSpan MD
By GLP-1 ScorecardUpdated
Score comparison
RxSpan MD has the higher recorded score — 84.3/100 to 49.9/100.
RxSpan MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. RxSpan MD's live catalog lists brand-name GLP-1 drugs, while its homepage also advertises compounded plans; confirm the actual product and total price before enrolling.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | AM Rx | RxSpan MD |
|---|---|---|
| WeighScore | 49.9/100 | 84.3/100 |
| Grade | C | B |
| Site position | #533 | #5 |
| Semaglutide | $151/mo (quarterly plan, plus a separate fee, compounded) | Current compounded quote unconfirmed |
| Tirzepatide | Not disclosed | Current compounded quote unconfirmed |
| Coverage | Coverage not published | Confirm treatment availability during intake |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #533 · C
FDAWarning letter issued to FitRX, LLC dba AM RX in June 2026. See the FDA warning-letter database.
Strengths
- Insurance coordination for brand-name GLP-1s — as low as $25/mo
- All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
- HSA and FSA accepted
- Video visits available with providers averaging 10+ years' experience
- Compounded semaglutide from $151/mo on the quarterly plan
What to consider
- Active FTC/DOJ lawsuit over deceptive billing and subscription practices
- Novo Nordisk false-advertising lawsuit (Aug 2025)
- Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
- Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
- FDA issued FitRX, LLC dba AM RX a warning letter in June 2026; the letter is public in FDA's warning-letter database
Site position #5 · B
Strengths
- Current public catalog lists Ozempic, Wegovy, Mounjaro and Zepbound
- Public terms describe independent healthcare providers
- Homepage describes messaging and care-team appointments
What to consider
- Homepage advertises compounded plans that the current catalog did not substantiate
- Current oral GLP-1 availability is unconfirmed
- Prior compounded prices are not a current quote; selected dose, supply, pharmacy and fee inclusions need confirmation
- Public terms do not establish unused prepaid-treatment refund amounts
Featured provider
RxSpan MD
RxSpan MD scores 84.3/100 (B). RxSpan MD's live catalog lists brand-name GLP-1 drugs, while its homepage also advertises compounded plans; confirm the actual product and total price before enrolling.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.